Research on EGFR-mutant cancer cell lines revealed that gefitinib resistance was associated with an oncogenic mutation in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA). Here, EGFR is linked to cancer.